Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 306

1.

[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S16-26. doi: 10.1055/s-0032-1305277. Epub 2013 Mar 25. German.

PMID:
23529567
[PubMed - indexed for MEDLINE]
2.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S.

Diabetes Obes Metab. 2011 Oct;13(10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x.

PMID:
21672123
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S.

Diabetes Obes Metab. 2013 May;15(5):432-40. doi: 10.1111/dom.12047. Epub 2013 Jan 25.

PMID:
23194084
[PubMed - indexed for MEDLINE]
4.

[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].

Nauck M, del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S6-15. doi: 10.1055/s-0032-1305283. Epub 2013 Mar 25. German.

PMID:
23529570
[PubMed - indexed for MEDLINE]
5.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.

Lancet. 2010 Jun 26;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2.

PMID:
20609968
[PubMed - indexed for MEDLINE]
6.

[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Studiengruppe Dapagliflozin 006.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S27-38. doi: 10.1055/s-0032-1305284. Epub 2013 Mar 25. German.

PMID:
23529568
[PubMed - indexed for MEDLINE]
7.

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

Rosenstock J, Vico M, Wei L, Salsali A, List JF.

Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.

PMID:
22446170
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators.

Cardiovasc Diabetol. 2013 Sep 5;12:129. doi: 10.1186/1475-2840-12-129.

PMID:
24007456
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G.

Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12.

PMID:
23850055
[PubMed - indexed for MEDLINE]
10.

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

Bailey CJ, Iqbal N, T'joen C, List JF.

Diabetes Obes Metab. 2012 Oct;14(10):951-9. doi: 10.1111/j.1463-1326.2012.01659.x. Epub 2012 Jul 24.

PMID:
22776824
[PubMed - indexed for MEDLINE]
11.

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group.

Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.

PMID:
22431673
[PubMed - indexed for MEDLINE]
12.

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J.

Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.

PMID:
23668478
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S.

J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.

PMID:
22238392
[PubMed - indexed for MEDLINE]
14.

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ.

Diabetes Care. 2011 Sep;34(9):2015-22. doi: 10.2337/dc11-0606. Epub 2011 Aug 4.

PMID:
21816980
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Plosker GL.

Drugs. 2012 Dec 3;72(17):2289-312. doi: 10.2165/11209910-000000000-00000. Review.

PMID:
23170914
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ.

Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185. Epub 2013 Aug 22.

PMID:
23906374
[PubMed - indexed for MEDLINE]
17.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF.

BMC Med. 2013 Feb 20;11:43. doi: 10.1186/1741-7015-11-43. Erratum in: BMC Med. 2013;11:193.

PMID:
23425012
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.

Diabetes Obes Metab. 2008 Nov;10(11):1047-56. doi: 10.1111/j.1463-1326.2008.00859.x. Epub 2008 Feb 18.

PMID:
18284434
[PubMed - indexed for MEDLINE]
19.

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.

Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF.

Int J Clin Pract. 2012 May;66(5):446-56. doi: 10.1111/j.1742-1241.2012.02911.x. Epub 2012 Mar 13.

PMID:
22413962
[PubMed - indexed for MEDLINE]
20.

Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.

Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S.

Diabetes Ther. 2014 Jun;5(1):267-83. doi: 10.1007/s13300-014-0072-0. Epub 2014 Jun 12.

PMID:
24920277
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk